Glenmark Pharmaceuticals announced its financial results for the second quarter and half-year ended September 30, 2026. Consolidated revenue for Q2 FY27 stood at ₹42,473 million, with a like-for-like growth of approximately 20% YoY. The company also highlighted advancements in its oncology pipeline, with key data selections and IND submissions planned. EBITDA for the quarter was ₹8,638 million, and Adjusted Profit After Tax was ₹4,852 million.
Glenmark Pharmaceuticals Reports Q2 FY27 Financial Results
Glenmark Pharmaceuticals Ltd. has announced its financial results for the second quarter and the half-year ended September 30, 2026. The company reported consolidated revenue of ₹42,473 million for the second quarter of FY27. On a like-for-like basis, this represents a year-over-year growth of approximately 20%.
Key Financial Highlights (Q2 FY27)
The company’s Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) for the quarter amounted to ₹8,638 million, with an EBITDA margin of 20.3%. Adjusted Profit After Tax (PAT) stood at ₹4,852 million, resulting in an adjusted PAT margin of 11.4%. The reported PAT was ₹2,638 million, with a reported PAT margin of 6.2%.
Regional Performance
Revenue from India formulations reached ₹13,274 million, showing significant growth. North America recorded revenue of ₹12,089 million, with the core business growing approximately 31% YoY on a like-for-like basis. Europe contributed ₹7,920 million in revenue, a growth of 6.2% YoY, while Emerging Markets generated ₹8,769 million, marking a growth of 33.2% YoY.
Strategic Pipeline Updates
Glenmark Pharmaceuticals also provided updates on its innovation pipeline. The company highlighted progress in its oncology assets, including the advancement of ISB 2001 (ABBV-2001) and plans to submit an IND application for ISB 2301 by the end of the current year. Updates were also provided on the development of immunology assets such as ISB 880 and ISB 830.
Management Commentary
Glenn Saldanha, Chairman & Managing Director, commented on the results, stating, “Q2 demonstrated the strength and resilience of Glenmark’s base business. We remain on track to deliver our FY27 guidance with continued growth in India, a strong recovery in North America supported by multiple launches, and robust performance across Emerging Markets.” He further emphasized the company’s commitment to innovation and long-term value creation.
About Glenmark Pharmaceuticals
Glenmark Pharmaceuticals Ltd. is a global, research-led pharmaceutical company focused on innovation and accessibility. It pioneers breakthrough therapies and provides high-quality, affordable medicines worldwide. With a diversified portfolio and a strong presence in key therapeutic areas, Glenmark aims to redefine treatment standards and expand patient access to essential healthcare solutions.
Source: BSE
